Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Later inzetten CDK4/6-remmer bij uitgezaaide borstkanker
dec 2024 | Borstkanker